ORMP
Price
$4.00
Change
-$0.00 (-0.00%)
Updated
Nov 3 closing price
Capitalization
166.39M
8 days until earnings call
Intraday BUY SELL Signals
XBIT
Price
$1.99
Change
+$0.07 (+3.65%)
Updated
Nov 3 closing price
Capitalization
60.67M
7 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ORMP vs XBIT

ORMP vs XBIT Comparison Chart in %
View a ticker or compare two or three
VS
ORMP vs. XBIT commentary
Nov 04, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ORMP is a Hold and XBIT is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for ORMP with price predictions
Nov 03, 2026

ORMP's MACD Histogram just turned positive

The Moving Average Convergence Divergence (MACD) for ORMP turned positive on October 27, 2026. Looking at past instances where ORMP's MACD turned positive, the stock continued to rise in 42 of 49 cases over the following month. The odds of a continued upward trend are 86%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ORMP's RSI Indicator exited the oversold zone, 23 of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.

The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.

Following a +1.56% 3-day Advance, the price is estimated to grow further. Considering data from situations where ORMP advanced for three days, in 216 of 263 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.

ORMP may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ORMP as a result. In 74 of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 81%.

ORMP moved below its 50-day moving average on October 01, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for ORMP crossed bearishly below the 50-day moving average on October 06, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 76%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ORMP declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.

The Aroon Indicator for ORMP entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is 15 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is 49 (best 1 - 100 worst), indicating steady price growth. ORMP’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of 65 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.524) is normal, around the industry mean (3.051). P/E Ratio (0.943) is within average values for comparable stocks, (-0.872). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.250) settles around the average of (125.677) among similar stocks. P/S Ratio (90.909) is also within normal values, averaging (439.647).

The Tickeron PE Growth Rating for this company is 93 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ORMP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

A.I.Advisor
a Summary for XBIT with price predictions
Nov 03, 2026

Momentum Indicator for XBIT turns negative, indicating new downward trend

XBIT saw its Momentum Indicator move below the 0 level on October 13, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 109 similar instances where the indicator turned negative. In 93 of the 109 cases, the stock moved further down in the following days. The odds of a decline are at 85%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for XBIT turned negative on October 16, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 55 similar instances when the indicator turned negative. In 46 of the 55 cases the stock turned lower in the days that followed. This puts the odds of success at 84%.

XBIT moved below its 50-day moving average on October 13, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where XBIT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.

The Aroon Indicator for XBIT entered a downward trend on October 08, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where XBIT's RSI Indicator exited the oversold zone, 22 of 32 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 69%.

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 47 of 70 cases where XBIT's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 67%.

Following a +5.85% 3-day Advance, the price is estimated to grow further. Considering data from situations where XBIT advanced for three days, in 130 of 194 cases, the price rose further within the following month. The odds of a continued upward trend are 67%.

XBIT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 32 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 72 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.472) is normal, around the industry mean (3.051). P/E Ratio (-1.345) is within average values for comparable stocks, (-0.872). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (4.965) settles around the average of (125.677) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (439.647).

The Tickeron Price Growth Rating for this company is 73 (best 1 - 100 worst), indicating slightly worse than average price growth. XBIT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. XBIT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

FUNDAMENTALS RATINGS
ORMP vs XBIT: Fundamental Ratings
ORMP
XBIT
OUTLOOK RATING
1..100
1282
VALUATION
overvalued / fair valued / undervalued
1..100
65
Fair valued
72
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
1597
PRICE GROWTH RATING
1..100
4973
P/E GROWTH RATING
1..100
9332
SEASONALITY SCORE
1..100
5085

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ORMP's Valuation (65) in the Pharmaceuticals Other industry is in the same range as XBIT (72) in the Biotechnology industry. This means that ORMP’s stock grew similarly to XBIT’s over the last 12 months.

ORMP's Profit vs Risk Rating (100) in the Pharmaceuticals Other industry is in the same range as XBIT (100) in the Biotechnology industry. This means that ORMP’s stock grew similarly to XBIT’s over the last 12 months.

ORMP's SMR Rating (15) in the Pharmaceuticals Other industry is significantly better than the same rating for XBIT (97) in the Biotechnology industry. This means that ORMP’s stock grew significantly faster than XBIT’s over the last 12 months.

ORMP's Price Growth Rating (49) in the Pharmaceuticals Other industry is in the same range as XBIT (73) in the Biotechnology industry. This means that ORMP’s stock grew similarly to XBIT’s over the last 12 months.

XBIT's P/E Growth Rating (32) in the Biotechnology industry is somewhat better than the same rating for ORMP (93) in the Pharmaceuticals Other industry. This means that XBIT’s stock grew somewhat faster than ORMP’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ORMPXBIT
RSI
ODDS (%)
Bullish Trend 1 day ago
77%
Bullish Trend 1 day ago
69%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
83%
Bullish Trend 1 day ago
67%
Momentum
ODDS (%)
Bearish Trend 1 day ago
81%
Bearish Trend 1 day ago
85%
MACD
ODDS (%)
Bullish Trend 1 day ago
86%
Bearish Trend 1 day ago
84%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
80%
Bullish Trend 1 day ago
71%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
81%
Bearish Trend 1 day ago
83%
Advances
ODDS (%)
Bullish Trend about 1 month ago
82%
Bullish Trend 1 day ago
67%
Declines
ODDS (%)
Bearish Trend 2 days ago
81%
Bearish Trend 5 days ago
80%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
78%
Bullish Trend 1 day ago
79%
Aroon
ODDS (%)
Bearish Trend 1 day ago
83%
Bearish Trend 1 day ago
85%
COMPARISON
Comparison
Nov 04, 2026
Stock price -- (ORMP: $4.00 vs. XBIT: $1.99)
Brand notoriety: ORMP and XBIT are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ORMP: 81% vs. XBIT: 226%
Market capitalization -- ORMP: $166.39M vs. XBIT: $60.67M
ORMP [@Biotechnology] is valued at $166.39M. XBIT’s [@Biotechnology] market capitalization is $60.67M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $134.53B. The average market capitalization across the [@Biotechnology] industry is $2.2B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ORMP’s FA Score shows that 1 FA rating(s) are green while XBIT’s FA Score has 1 green FA rating(s).

  • ORMP’s FA Score: 1 green, 4 red.
  • XBIT’s FA Score: 1 green, 4 red.
According to our system of comparison, ORMP is a better buy in the long-term than XBIT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ORMP’s TA Score shows that 5 TA indicator(s) are bullish while XBIT’s TA Score has 4 bullish TA indicator(s).

  • ORMP’s TA Score: 5 bullish, 5 bearish.
  • XBIT’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, ORMP is a better buy in the short-term than XBIT.

Price Growth

ORMP (@Biotechnology) experienced а -3.85% price change this week, while XBIT (@Biotechnology) price change was +7.57% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.09%. For the same industry, the average monthly price growth was -12.05%, and the average quarterly price growth was -17.02%.

Reported Earning Dates

ORMP is expected to report earnings on Nov 12, 2026.

XBIT is expected to report earnings on Nov 11, 2026.

Industries' Descriptions

@Biotechnology (-2.09% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
ORMP
Daily Signal:
Gain/Loss:
XBIT
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
IREG2.390.42
+21.32%
Leverage Shares 2X Long IREN Daily ETF (IREG)
IWC177.250.89
+0.50%
iShares Micro-Cap ETF (IWC)
GLV5.780.01
+0.17%
Clough Global Dividend and Income Fund
HYGM23.62N/A
N/A
Amplify HYG High Yield 10% Target Income ETF (HYGM)
TMVE17.82-0.07
-0.40%
Thrivent Mid Cap Value ETF (TMVE)